Triacsin C

Triacsin C (WS 1228A), is an orally active and intracellular long-chain acyl-CoA synthetases (ACSL) inhibitor, which can be isolated from Streptomyces aureofaciens. Triacsin C inhibits TAG accumulation into lipid droplets (LD) by suppressing ACSL activity[1]. Triacsin C exhibits highly inhibitory effect against rotavirus replication[2].

Product Specifications

CAS Number

[76896-80-5]

Product Name Alternative

WS 1228A; FR 900190

UNSPSC

12352211

Hazard Statement

H315, H319, H335

Target

Parasite

Type

Natural Products

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/triacsin-c.html

Purity

99.08

Solubility

DMSO : 5 mg/mL (ultrasonic; warming)

Smiles

CCC/C=C/C/C=C/C=C/C=N/NN=O

Molecular Formula

C11H17N3O

Molecular Weight

207.27

Precautions

H315, H319, H335

References & Citations

[1]Dechandt CRP, et al. Triacsin C reduces lipid droplet formation and induces mitochondrial biogenesis in primary rat hepatocytes. J Bioenerg Biomembr. 2017 Oct;49 (5) :399-411.|[2]Kim Y, et al. Novel triacsin C analogs as potential antivirals against rotavirus infections. Eur J Med Chem. 2012 Apr;50:311-8.|[3]Guo F, et al. Amelioration of Cryptosporidium parvum infection in vitro and in vivo by targeting parasite fatty acyl-coenzyme A synthetases. J Infect Dis. 2014 Apr 15;209 (8) :1279-87. |[4]Matsuda D, et al. Anti-atherosclerotic activity of triacsin C, an acyl-CoA synthetase inhibitor. J Antibiot (Tokyo) . 2008 May;61 (5) :318-21.